Shanxi Zhendong Pharmaceutical (300158) — Net Asset Quality Index
Shanxi Zhendong Pharmaceutical (300158) has a Net Asset Quality Index of 80.4% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.51 Billion minus total liabilities of CN¥882.65 Million yields net assets of CN¥3.63 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 300158 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shanxi Zhendong Pharmaceutical Net Asset Quality Index Over Time (2007–2024)
This chart shows how Shanxi Zhendong Pharmaceutical's Net Asset Quality Index has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the index stands at 80.4%, representing net assets of CN¥3.63 Billion against total assets of CN¥4.51 Billion CNY. See Shanxi Zhendong Pharmaceutical working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shanxi Zhendong Pharmaceutical (2007–2024)
The table below presents the year-by-year Net Asset Quality Index for Shanxi Zhendong Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 300158 stock market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 73.5% | CN¥3.66 Billion | CN¥4.98 Billion | CN¥1.32 Billion | ▼ -9.8 pp |
| 2023 | 83.2% | CN¥5.14 Billion | CN¥6.18 Billion | CN¥1.04 Billion | ▲ +3.5 pp |
| 2022 | 79.7% | CN¥5.22 Billion | CN¥6.55 Billion | CN¥1.33 Billion | ▼ -0.1 pp |
| 2021 | 79.8% | CN¥8.05 Billion | CN¥10.09 Billion | CN¥2.04 Billion | ▲ +5.7 pp |
| 2020 | 74.1% | CN¥5.63 Billion | CN¥7.60 Billion | CN¥1.97 Billion | ▼ -4.6 pp |
| 2019 | 78.7% | CN¥5.44 Billion | CN¥6.92 Billion | CN¥1.47 Billion | ▲ +4.3 pp |
| 2018 | 74.3% | CN¥5.36 Billion | CN¥7.21 Billion | CN¥1.85 Billion | ▲ +1.3 pp |
| 2017 | 73.0% | CN¥5.56 Billion | CN¥7.61 Billion | CN¥2.06 Billion | ▼ -3.7 pp |
| 2016 | 76.7% | CN¥5.27 Billion | CN¥6.87 Billion | CN¥1.60 Billion | ▲ +26.8 pp |
| 2015 | 49.9% | CN¥2.03 Billion | CN¥4.07 Billion | CN¥2.04 Billion | ▼ -19.0 pp |
| 2014 | 68.9% | CN¥1.97 Billion | CN¥2.86 Billion | CN¥888.23 Million | ▼ -1.1 pp |
| 2013 | 70.0% | CN¥1.96 Billion | CN¥2.80 Billion | CN¥838.64 Million | ▼ -3.5 pp |
| 2012 | 73.5% | CN¥1.90 Billion | CN¥2.58 Billion | CN¥684.26 Million | ▼ -8.9 pp |
| 2011 | 82.4% | CN¥1.86 Billion | CN¥2.26 Billion | CN¥397.40 Million | ▲ +0.3 pp |
| 2010 | 82.1% | CN¥1.78 Billion | CN¥2.17 Billion | CN¥389.13 Million | ▲ +26.2 pp |
| 2009 | 55.9% | CN¥359.31 Million | CN¥643.18 Million | CN¥283.87 Million | ▲ +2.2 pp |
| 2008 | 53.7% | CN¥266.72 Million | CN¥496.69 Million | CN¥229.98 Million | ▲ +15.9 pp |
| 2007 | 37.8% | CN¥176.42 Million | CN¥466.70 Million | CN¥290.28 Million | — |